Cis and trans stereoisomers of amiclenomycin, a natural l-amino acid antibiotic, have been prepared using unequivocal routes. By using 1 H NMR spectroscopy, the configuration of the six-membered ring of natural amiclenomycin was shown to be cis and not trans as originally proposed. Amiclenomycin and some synthetic analogues with the cis configuration irreversibly inactivate DAPA AT (7,8-diaminopelargonic acid aminotransferase), an enzyme involved in biotin biosynthesis, by forming an aromatic PLP (pyridoxal-5 -phosphate)-inhibitor adduct that is tightly bound to the active site. The following kinetic parameters for the inactivation of Escherichia coli DAPA AT by amiclenomycin were derived: K I = 2 µM and k inact = 0.4 min −1 .
Introduction
In 1974, Okami and co-workers isolated a new amino acid antibiotic, amiclenomycin 1a (Scheme 1), from culture filtrates of Streptomyces lavendulae [1] [2] [3] . It was also isolated later, incorporated in di-or tripeptide, from Streptomyces venezulae [4, 5] . Okami and co-workers reported that amiclenomycin inhibited the growth of mycobacteria and that its target was DAPA AT (7, 8 -diaminopelargonic acid aminotransferase), a PLP (pyridoxal-5 -phosphate)-dependent enzyme involved in biotin biosynthesis [1] [2] [3] . However, the proposed stereochemistry for amiclenomycin proved to be wrong and the mode of action of this antibiotic was not completely understood.
Because biotin biosynthesis is unique to plants and microorganisms, and is thus an attractive target for herbicides and antibiotics, we decided to reexamine the mechanism by which amiclenomycin inhibits DAPA AT. Total synthesis of this unusual amino acid was necessary because the natural compound was no longer available and because we speculated that the trans configuration proposed by Okami et al. [1] was ambiguous and needed confirmation. We thus undertook the synthesis of cis-and trans-amiclenomycin (1a and 1b) using two unequivocal routes (Scheme 2) [6, 7] . As shown below, we obtained cis-and trans-amiclenomycin and analogues, and unambiguously assigned the cis configuration to the natural antibiotic, in contrast with the assignment tentatively proposed by Okami.
Inactivation of Escherichia coli DAPA AT by amiclenomycin and analogues was carefully studied using different approaches and was shown to be irreversible with the formation of an aromatic PLP-amiclenomycin adduct 2 that is tightly bound to the active site (Scheme 3) [8] [9] [10] . The natural cis-amiclenomycin 1a was much more efficient than the trans compound 1b, confirming our stereochemical assignment.
It was recently reported that bioA, the gene encoding for DAPA AT, was implicated in long-term survival of mycobacteria [11] . We thus overexpressed and purified DAPA AT from Mycobacterium tuberculosis for characterization and structural studies of this potential drug target.
Synthesis of amiclenomycin and analogues
The strategy we chose to construct the amino-cyclohexadiene is based on a Diels-Alder cycloaddition between a (1E, 3E)-diene 3 and a synthetic equivalent of acetylene, since acetylene itself is not reactive enough (Scheme 2). We thus used (E)-1,2-bis-(phenylsulphonyl)-ethylene 4 as the dienophile to obtain the cyclic compound 5 with the cis configuration. Reductive elimination of the sulphonyl groups afforded 6a with a cis-amino-cyclohexadiene ring. The trans-stereoisomer was obtained starting from a protected enol ether 3 (R 1 = OP ) and using a Mitsunobu reaction, in the presence of an amino nucleophile, to invert the stereocentre of 5, leading to 7. Reductive desulphonylation of 7 afforded 6b with the transamino-cyclohexadiene ring.
The amino acid functionality was introduced in the same manner for both stereoisomers. The primary alcohol (side This synthetic route is quite general and was successfully applied to the synthesis of diverse amiclenomycin analogues with various side chains (R 2 in Scheme 2) such as 9 and 10, starting from the appropriate diene 3.
The long range 5 J scalar coupling constant for the allylic protons of 1a and 1b, as measured by 1 H NMR, gave 8.1 and 5.6 Hz for the cis and trans compounds respectively. Okami et al. [1] measured a coupling constant of 5 J = 7.5 Hz on the isolated amiclenomycin, a value close to that measured by us for the cis-isomer. We thus proved here that the configuration of natural amiclenomycin is cis and not trans as originally proposed.
Irreversible inactivation of DAPA AT by amiclenomycin and analogues

Kinetic experiments
Steady-state kinetic characterization of the E. coli DAPA AT was first reported by Stoner and Eisenberg [12, 13] , while more recently, Kirsch and co-workers conducted rapid kinetic experiments [14] . DAPA AT shows a classical Ping Pong Bi Bi kinetic mechanism, with S-adenosylmethionine being the amino donor, a unique feature among aminotransferases. The steady-state kinetic parameters for the native DAPA AT are the following:
Strong substrate inhibition by KAPA (K I = 25 µM) was also noted. The E. coli recombinant enzyme purified in our laboratory from an overexpression construct [15] behaved similarly with a slightly lower k cat of 0.08 s −1 . For determination of DAPA AT activity, we used a sensitive coupled assay by converting DAPA to DTB (dethiobiotin) using purified DTB synthetase in the presence of its substrates. DTB was then directly quantified by a standard disc bioassay.
Inhibition by amiclenomycin and analogues was studied by preincubating DAPA AT with the inhibitor, for various time scales, and measuring the residual DAPA AT activity, after dilution. While amiclenomycin 1a and the analogues with the cis configuration showed strong time-dependent inhibition, the compounds with the trans configuration showed little or no inhibition. These data corroborate the stereochemical assignment we made for natural amiclenomycin. The inactivation by amiclenomycin 1a and cis-analogues resisted prolonged dialysis, a common criterion for irreversible inactivation. Complete kinetic characterization was Scheme 2 Outline of the synthesis of amiclenomycin, its trans stereoisomer and derivatives P and P refer to protecting groups [6, 7] .
Scheme 3
Proposed mechanism for the irreversible inactivation of DAPA AT by amiclenomycin and minimal kinetic scheme conducted on amiclenomycin 1a, the most potent inhibitor, and on 3a, a less potent inhibitor. Fitting the data to a simple two-step kinetic mechanism with rapid pre-equilibrium (Scheme 3) gave for 1a, K I = 2 µM and k inact = 0.4 min −1 and for 3a, K I = 15 µM and k inact = 0.7 min −1 . While amiclenomycin binds as tightly as the substrate KAPA, the inactivation process is somewhat slower than catalysis with a k inact / K I = 3 × 10 3 M −1 · s −1 .
Structural evidence supporting the mechanism
The mechanism of inactivation by amiclenomycin 1a, and hence by analogues, relies on three lines of evidence. First, we showed that upon reaction with DAPA AT all cis-inactivators induced a bleaching of DAPA AT absorption at 420 nm and an increase in absorption at 320 nm. This was interpreted as the conversion of the internal lysine-PLP aldimine to a pyridoxamine structure. Secondly, the crystal structure of the inactivated DAPA AT by amiclenomycin 1a was solved at 1.8 Å (1 Å = 0.1 nm) resolution and compared with the threedimensional structure of the ternary complex DAPA AT-PLP-KAPA [16] . The structure revealed the presence of an amiclenomycin-PLP adduct non-covalently bound to the protein, although it was difficult at that resolution to distinguish between an aromatic ring and a quasi-planar cyclohexadiene ring. The amiclenomycin moiety of the adduct is located in the KAPA binding site, constituted of aromatic residues (Tyr  17 , Tyr  144 , Trp  52 and Trp  53 ) . Finally, we established the definite proof of the formation of the aromatic adduct by using ESI (electrospray ionization)-MS. Using sufficient ionization energy, the adduct 2 dissociated from the inactivated enzyme complex, and its molecular ion was detected at m/z 426. Fragmentations were in total agreement with those reported by us [9] , for an authentic aromatic adduct 2, prepared independently. Analysis by ESI-MS of DAPA AT inactivated by cis-analogues of amiclenomycin, also showed the formation of an aromatic adduct. The proposed mechanism in Scheme 3 is thus operative for all compounds of this series. This mechanism is reminiscent of that proposed by Rando [17] for the inactivation of GABA transaminase by gabaculine and more recently by others for the inactivation of GABA transaminase [18] , D-amino acid aminotransferase [19] , and alanine racemase [20] by cycloserine. It is quite interesting to note that all these PLPdependent enzymes are inhibited by a similar mechanism ultimately yielding an aromatic ring that does not dissociate from the active site. Careful structural analysis of these enzyme-inhibitor complexes should help in defining the molecular basis for the high affinity of the aromatic adduct.
M. tuberculosis DAPA AT as a potential drug target
Despite an effective antibiotic regimen, tuberculosis remains a major threat in the world. Furthermore, the appearance of resistant M. tuberculosis strains to conventional antibiotics, makes the need for new antituberculous drugs even more urgent. Because amiclenomycin inhibits the growth of mycobacteria and because bioA gene has been implicated recently in the long-term survival of mycobacteria, we have undertaken the purification and characterization of M. tuberculosis DAPA AT.
An engineered DNA insert containing a ribosome-binding site and an N-terminal His 6 -tagged bioA gene flanked by two restriction sites has been amplified by conventional PCR. Cloning into plasmid pUC18 provided an efficient expression vector for M. tuberculosis DAPA AT. Expression in transformed E. coli Rosetta strain gave large quantities of DAPA AT, but unfortunately, mostly in an insoluble form. However, a one-step purification by nickel affinity chromatography, performed on the soluble fraction, yielded a pure enzyme as judged by SDS/PAGE analysis. DAPA AT thus obtained is active and shows a characteristic electronic absorption spectrum for the PLP-dependent enzyme (λ max at 320 and 420 nm). Biochemical characterization of this enzyme and, in particular, its inactivation by amiclenomycin and its analogues is underway. The high purity of the protein will certainly facilitate the crystallization of this potential therapeutic target, for structural studies.
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